Literature DB >> 31679265

The Molecular Mechanism of EPO Regulates the Angiogenesis after Cerebral Ischemia through AMPK-KLF2 Signaling Pathway.

Guang-Hui Chen1, Xiao-Li Li2, Yan-Qing Deng2, Fa-Ming Zhou2, Wen-Qin Zou2, Wen-Xin Jiang2, Shou-Qin Shangguan2, Zu-Neng Lu3.   

Abstract

OBJECTIVE: In this study, the molecular mechanism by which EPO regulates the angiogenesis after cerebral ischemia through AMPK-KLF2 signaling pathway was investigated.
METHODS: Sixty healthy, male, C57BL/6 mice were randomly divided into three groups of 20 mice: a sham group, the middle cerebral artery occlusion (MCAO) group, and a MCAO+EPO treatment group. The MCAO model was established using a modified ZeaLonga method. Mice in the EPO treatment group were injected with EPO immediately after reperfusion (5000 IU/kg), and EPO was injected the following day. The number of mouse deaths and neurologic function scores were recorded during the experiment. On day 7 after cerebral ischemia, brain tissue proteins were extracted. The following proteins expressions were detected by western blot assay: EPO, vascular endothelial growth factor (VEGE), vascular endothelial growth factor receptor (KDR), adenosine activated protein kinase (AMPK), and alpha HIF-1α alpha (HIF-1α), KLF2 and nitric oxide synthase (eNOS).
RESULTS: Compared with the MCAO group, the survival rate of mice in the EPO group was significantly improved and neurological function was significantly improved (P < 0.01). Western blot results showed that the content of EPO in brain tissue in MCAO group significantly increased compared with sham group. The content of EPO in the brain tissue of mice in the MCAO+EPO treatment group was significantly higher than in that of the MCAO group, which indicates that EPO increased the content of EPO in mouse brain tissue. Compared with the sham group, the protein expression of vascular endothelial growth factor (VEGE) and its receptor (KDR) in brain tissue of the MCAO group significantly decreased. However, the protein expression of VEGE and its receptor KDR in brain tissue of rats treated with MCAO+EPO was significantly higher than in that of the MCAO group. Thus, in this study, EPO was associated with vascular endothelial differentiation after cerebral ischemia in mice. The results of AMPK and KLF2 showed that the expression levels of AMPK and KLF2 in brain tissues of MCAO group mice significantly decreased compared with the sham group. However, the expression levels of AMPK and KLF2 in brain tissues of mice treated with MCAO+EPO were significantly higher than those in the MCAO group. Thus, EPO can activate AMPK and upregulate the expression of the transcription factor KLF2. The protein expression of HIF-1α in the brain tissue of mice in the MCAO group significantly increased compared with the sham group. However, the expression of HIF-1α in mice brain tissues in the MCAO+EPO treatment group was significantly lower than in that of the MCAO group, indicating that EPO was involved in regulating HIF-1α expression. The eNOS results showed that, compared with Sham group, the protein expression of eNOS in brain tissue of MCAO group mice significantly decreased. In the MCAO+EPO treatment group, the protein expression of eNOS was significantly higher in the brain tissue of the mice than in that of the MCAO group, indicating that EPO was involved in the synthesis of NO and promoted the angiogenesis.
CONCLUSION: EPO promotes VEGE and its receptor (KDR) expression and participates in the regulation of HIF-1α and eNOS protein expression through the activation of AMPK-KLF2 signaling pathways to promote new vascular development after cerebral ischemia.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31679265     DOI: 10.1615/CritRevEukaryotGeneExpr.2019029018

Source DB:  PubMed          Journal:  Crit Rev Eukaryot Gene Expr        ISSN: 1045-4403            Impact factor:   1.807


  7 in total

1.  RGS6 Drives Spinal Cord Injury by Inhibiting AMPK Pathway in Mice.

Authors:  Wenxin Dao; Zhe Xiao; Weize Yang; Xiaomin Luo; Hongxia Xia; Zuneng Lu
Journal:  Dis Markers       Date:  2022-04-25       Impact factor: 3.464

2.  Baicalin Inhibits NLRP3 Inflammasome Activity Via the AMPK Signaling Pathway to Alleviate Cerebral Ischemia-Reperfusion Injury.

Authors:  Wen-Xia Zheng; Wen-Qi He; Qian-Rui Zhang; Jin-Xin Jia; Sheng Zhao; Fang-Jian Wu; Xiao-Lu Cao
Journal:  Inflammation       Date:  2021-06-02       Impact factor: 4.092

3.  Investigation of Neuroprotective Effects of Erythropoietin on Chronic Neuropathic Pain in a Chronic Constriction Injury Rat Model.

Authors:  Kai Zhang; Junhao Wang; Haiyang Xi; Lepeng Li; Zhaohui Lou
Journal:  J Pain Res       Date:  2020-11-30       Impact factor: 3.133

4.  KLF2 up-regulates IRF4/HDAC7 to protect neonatal rats from hypoxic-ischemic brain damage.

Authors:  Fan Wu; Chunlin Li
Journal:  Cell Death Discov       Date:  2022-01-28

Review 5.  The Role of KLF2 in the Regulation of Atherosclerosis Development and Potential Use of KLF2-Targeted Therapy.

Authors:  Siarhei A Dabravolski; Vasily N Sukhorukov; Vladislav A Kalmykov; Andrey V Grechko; Nikolay K Shakhpazyan; Alexander N Orekhov
Journal:  Biomedicines       Date:  2022-01-24

Review 6.  The Effect of Erythropoietin and Its Derivatives on Ischemic Stroke Therapy: A Comprehensive Review.

Authors:  Yuanyuan Ma; Zhiyuan Zhou; Guo-Yuan Yang; Jing Ding; Xin Wang
Journal:  Front Pharmacol       Date:  2022-02-17       Impact factor: 5.810

7.  ERK5 Is a Major Determinant of Chemical Sarcomagenesis: Implications in Human Pathology.

Authors:  Elena Arconada-Luque; Jaime Jiménez-Suarez; Raquel Pascual-Serra; Syong Hyun Nam-Cha; Teresa Moline; Francisco J Cimas; Germán Fliquete; Marta Ortega-Muelas; Olga Roche; Diego M Fernández-Aroca; Raúl Muñoz Velasco; Natalia García-Flores; Cristina Garnés-García; Adrián Sánchez-Fdez; Sofía Matilla-Almazán; Víctor J Sánchez-Arévalo Lobo; Javier Hernández-Losa; Borja Belandia; Atanasio Pandiella; Azucena Esparís-Ogando; Santiago Ramón Y Cajal; Luis Del Peso; Ricardo Sánchez-Prieto; María José Ruiz-Hidalgo
Journal:  Cancers (Basel)       Date:  2022-07-19       Impact factor: 6.575

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.